#USA #Philadelphia #Berger Montague #MASH #Altimmune

Investigating Altimmune: Potential Class Action Lawsuit

As of September 25, 2025, Berger Montague PC has initiated an investigation into potential federal securities law violations committed by Altimmune, Inc. (NASDAQ: ALT). Altimmune, dedicated to developing therapeutics for conditions related to obesity and liver diseases, including the serious metabolic disorder known as metabolic dysfunction-associated steatohepatitis (MASH), has recently wrestled with a class action lawsuit that has raised alarms among its investors.

Background on Altimmune

Altimmune is a biopharmaceutical company that has been focusing its R&D efforts on treatments addressing severe health concerns, particularly obesity and liver ailments. The company's flagship product, Pemvidutide, was under scrutiny following the announcement of its Phase 2b trial results on June 26, 2025. Management had previously emphasized optimism regarding these results but ultimately failed to demonstrate significant efficacy. This discrepancy has resulted in a steep decline of Altimmune's stock, falling from $7.71 to $3.61—a staggering drop of over 53% in just one day.

Class Action Details

The critical period during which securities were acquired stretches from August 10, 2023, to June 25, 2025. It is during this timeframe that investors are encouraged to seek representation as lead plaintiffs in the matter. October 6, 2025, has been set as the deadline for these actions, and potential investors are urged to act quickly to protect their rights.

The case gained traction after Altimmune's June press release highlighted not just a disappointing outcome but an unexpected placebo response that complicated their interpretations of trial data. Although the company conveyed positivity about the results, the data did not reflect anticipated improvements in fibrosis reduction and raised concerns regarding their clinical trial methodology.

What You Need To Know

Investors seeking to understand their legal rights regarding this matter can reach out to Berger Montague. Interested parties should contact representatives Andrew Abramowitz or Caitlin Adorni, who specialize in securities litigation. They have extended a warm invitation to discuss individual cases and represent interested investors in this unfolding litigation.

Conclusion

Berger Montague has a long-standing reputation in securities class action litigation since its foundation in 1970. With extensive experience in representing individual and institutional investors, the firm stands prepared to navigate the complexities levelled against Altimmune, reassuring their commitment to holding companies accountable. It’s essential for affected investors to stay informed and act swiftly in these circumstances to safeguard their investments.

For further inquiries, please reach out to Andrew Abramowitz at [email protected] or Caitlin Adorni at [email protected] for more details on this emerging legal action against Altimmune and their implications for shareholders.